Luca Roncati | Pharmacovigilance | Best Academic Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Luca Roncati | Pharmacovigilance | Best Academic Researcher Award

Link Campus University | Italy

Prof. Dr. Luca Roncati is a distinguished Italian pathologist, physician-scientist, and academic leader whose extensive contributions have significantly advanced modern medical science. With a strong focus on senology, gynecologic oncology, gynecopathology, and hematopathology, he stands as a prominent figure in the global medical community. Dr. Roncati has an impressive record of 228 scientific publications, collectively cited in over 1,073 documents with more than 1,738 total citations, reflecting the profound influence and credibility of his research across various medical disciplines.Renowned for his groundbreaking discoveries, Dr. Roncati is the eponym of the Roncati–Manenti Triad, a key diagnostic concept in gynecologic oncology, and the describer of T rex lymphoma, a rare hematological condition that broadened the understanding of lymphoid malignancies. As a pioneering researcher in COVID-19, his investigations provided critical insights into viral pathogenesis and immune mechanisms, shaping the scientific response during the global pandemic. Furthermore, his innovative work in nanopathology has paved the way for the integration of nanotechnology into modern diagnostic pathology, offering revolutionary approaches to disease detection at the molecular level.Beyond research, Dr. Roncati is a full-time Professor of Pathology at Link Campus University in Rome, where he mentors future medical professionals and drives forward-thinking educational programs in biomedical sciences. Simultaneously, he leads as the Head of the Women’s Health Department at the European Institute of Dermatology in Milan, where his expertise in women’s health, oncology, and diagnostic pathology enhances patient care and clinical outcomes.An award-winning author, academic editor, and inventor of anti-cancer patents, Dr. Roncati’s contributions exemplify the synergy between innovation, clinical excellence, and scientific discovery. His scholarly achievements, coupled with his dedication to advancing medical knowledge, have established him as one of the most influential figures in contemporary pathology and translational medicine. Through his research, publications, and leadership, Prof. Dr. Luca Roncati continues to inspire a new generation of scientists and clinicians in their pursuit of excellence and innovation in healthcare.

Profile: Scopus

Featured Publications

Roncati, L., et al. (2025). Erratum: Long COVID clinical evaluation, research and impact on society: a global expert consensus. Annals of Clinical Microbiology and Antimicrobials.

Roncati, L., et al. (2025). Long COVID clinical evaluation, research and impact on society: a global expert consensus. Annals of Clinical Microbiology and Antimicrobials.

Roncati, L., et al. (2025). pDNA impurities in mRNA vaccines. Editorial, Open Access.

Roncati, L., et al. (2025). Thoracic aortic pseudoaneurysm: Inside its pathophysiology. Vascular.

Roncati, L., et al. (2025). Adjuvant metronomic chemotherapy after surgery in pT1–T2 N0 M0 HER2-positive and ER/PR-positive breast cancer plus targeted therapy, anti-hormonal therapy, and radiotherapy, with or without immunotherapy: A new operational proposal. Editorial, Open Access.

Roncati, L., et al. (2025). Ozone–oxygen therapy to prevent HPV-related cancers of the lower gynecological tract in infected patients: The rationale for further developments. Cancers. [Open Access]

Roncati, L., et al. (2025). COVID-19 and upper limb compression neuropathies: A review. Review Article, Open Access.

Karanvir Singh | Medicinal Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Mr. Karanvir Singh | Medicinal Chemistry | India

Guru Nanak Dev University | India

Mr. Karanvir Singh is a dynamic and highly skilled researcher in the field of pharmaceutical chemistry, currently pursuing his Doctorate of Philosophy at the Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India. His ongoing doctoral research, under the supervision of Prof. Dr. Preet Mohinder Singh Bedi, focuses on the design and synthesis of 1,2,4-triazine hybrids with Nipecotic acid for anticonvulsant activity, emphasizing computational modeling, synthesis, and biological evaluation of novel anticonvulsant agents. He holds a Master’s degree in Pharmacy (Pharmaceutical Chemistry) from ISF College of Pharmacy, Moga, Punjab, where he completed a thesis on the design and synthesis of 1,2,4-triazine derivatives for anticonvulsant activity under the guidance of Dr. Vikramdeep Monga and Dr. Bhupinder Kumar. His strong academic foundation was built upon a Bachelor of Pharmacy from the Laureate Institute of Pharmacy, Himachal Pradesh.With a blend of academic excellence and industrial exposure, Mr. Singh has worked as an Assistant QA Chemist at United Biotech Pvt. Ltd., where he gained extensive experience in pharmaceutical quality assurance. His scientific expertise spans molecular docking, fragment-based drug design, pharmacophore modeling, molecular dynamics simulations, organic synthesis, compound purification, and structural elucidation using analytical tools such as NMR, FT-IR, HPLC, and Mass spectrometry.Mr. Singh has made significant contributions to the scientific community, authoring multiple research and review articles in reputed journals. His notable publications include Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan–Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy; Design, Synthesis, and Multi-Target Biological Evaluation of 1,2,3-Triazole Linked Indole–Thiazolidinedione Hybrids as Potent α-Glucosidase, α-Amylase, and DPP-4 Inhibitors with Antioxidant Potential; Design, Synthesis, Antibacterial Evaluation, and Molecular Modelling Studies of 1,2,3-Triazole-Linked Coumarin–Vanillin Hybrids as Potential DNA Gyrase and Topoisomerase IV Inhibitors; and Development of Coumarin-Inspired Bifunctional Hybrids as a New Class of Anti-Alzheimer’s Agents with Potent In Vivo Efficacy. His review works, such as Exploring Norfloxacin Analogs in Combating Antimicrobial Resistance: Design, Mechanistic Insights, and Structure–Activity Relationship and Incredible Indolinedione Derivatives Nucleus in the Development of Anti-Diabetic Drugs: Exploring the Mechanistic Studies, Design, and Structure–Activity Relationship, further demonstrate his broad research vision and scientific depth.

Profile: Google Scholar

Featured Publications

Singh, K., Pal, R., Khan, S. A., Kumar, B., & Akhtar, M. J. Insights into the structure–activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review. Journal of Molecular Structure.

Singh, A., Malhotra, D., Singh, K., Chadha, R., & Bedi, P. M. S. Thiazole derivatives in medicinal chemistry: Recent advancements in synthetic strategies, structure–activity relationship, and pharmacological outcomes. Journal of Molecular Structure.

Singh, A., Singh, K., Sharma, A., Kaur, K., Kaur, K., Chadha, R., & Bedi, P. M. S. Recent developments in synthetic α-glucosidase inhibitors: A comprehensive review with structural and molecular insight. Journal of Molecular Structure.

Pal, R., Singh, K., Khan, S. A., Chawla, P., Kumar, B., & Akhtar, M. J. Reactive metabolites of the anticonvulsant drugs and approaches to minimize the adverse drug reaction. European Journal of Medicinal Chemistry.

Singh, A., Singh, K., Sharma, A., Kaur, K., Chadha, R., & Bedi, P. M. S. Recent advances in antifungal drug development targeting lanosterol 14α-demethylase (CYP51): A comprehensive review with structural and molecular insights. Chemical Biology & Drug Design.

Samaneh Moradi | Antibiotic Resistance | Best Faculty Award

Published on by Top Pharmaceutical

Dr. Samaneh Moradi | Antibiotic Resistance | Best Faculty Award

Golestan University | Iran

Dr. Samaneh Moradi is a distinguished researcher and educator specializing in medical microbiology, with a strong academic foundation from the Department of Microbiology, Faculty of Science, Golestan University, Gorgan, Iran. She holds a Ph.D. in Medical Microbiology, where her doctoral research was centered on a systematic review of the prevalence of antibacterial resistance in Enterococcus faecalis outside clinical settings, with a particular emphasis on animals, food, and environmental sources. Her work reflects a deep commitment to understanding the complex pathways of bacterial resistance and its implications for both human and environmental health.With over 12 years of hands-on laboratory and research experience, Dr. Moradi has developed extensive expertise in a wide range of microbiological and molecular biology techniques. Her practical experience includes conducting ELISA assays, utilizing advanced diagnostic platforms such as Cobas e411, Immulite 200, and Sysmex instruments, as well as performing cell counting and viability assessments through both automated and manual methods. She has worked proficiently with cell culture models such as Caco-2 cells, enabling her to explore host-pathogen interactions and antimicrobial responses at the cellular level. Her proficiency further extends to real-time PCR, Western blotting, and microbial diagnostics and identification, underscoring her technical versatility and analytical precision.Dr. Moradi’s research contributions include several peer-reviewed publications, with five articles published and three additional manuscripts recently submitted for consideration. Her work integrates advanced immunoassays, molecular biology, and clinical microbiology diagnostics, reflecting her multidisciplinary approach to microbial research. She is also well-versed in statistical data analysis and interpretation, frequently employing SPSS software for data-driven insights that enhance the validity and reliability of her scientific outcomes.Her scientific journey is characterized by a balance of academic excellence and practical expertise, enabling her to contribute meaningfully to contemporary challenges in infectious diseases, antibiotic resistance, and diagnostic innovation. Based at the Department of Microbiology, Golestan University, Dr. Samaneh Moradi continues to advance microbiological research through her dedication, precision, and pursuit of knowledge aimed at improving public health outcomes and microbial understanding across clinical and environmental domains.

Profile: Google Scholar

Featured Publications

Guan, L., Beig, M., Wang, L., Navidifar, T., Moradi, S., Motallebi Tabaei, F., & others. (n.d.). Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: Systematic review and meta-analysis. Annals of Clinical Microbiology and Antimicrobials.

Huang, C., Moradi, S., Sholeh, M., Tabaei, F. M., Lai, T., Tan, B., Meng, J., & Azizian, K. (n.d.). Global trends in antimicrobial resistance of Enterococcus faecium: A systematic review and meta-analysis of clinical isolates. Frontiers in Pharmacology.

Farsimadan, M., Heravi, F. S., Emamvirdizadeh, A., Moradi, S., Iranpour, H., & others. (n.d.). Evaluation of Helicobacter pylori genotypes in obese patients with gastric ulcer, duodenal ulcer, and gastric cancer: An observational study. Digestive Diseases.

Yang, Y., Yeganeh, R., Moghadam, M. A., Teymouri, Z., Tabaei, F. M., Moradi, S., & others. (n.d.). Global antibiotic resistance trends in Enterococcus faecalis from animals, food, and environmental sources: A meta-analysis. Preventive Veterinary Medicine.

Aleksandra Klisic | Cardiovascular Pharmacology | Best Research Article Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Aleksandra Klisic | Cardiovascular Pharmacology | Best Research Article Award

University of Montenegro-Faculty of Medicine | Montenegro

Assoc. Prof. Dr. Aleksandra Klisic is a distinguished medical scientist and academic leader from Montenegro, currently serving as an Associate Professor at the University of Montenegro, Faculty of Medicine, Podgorica. She also holds prominent positions as Chief and Quality Manager at the Center for Laboratory Diagnostics, Primary Health Care Center in Podgorica. With a strong foundation in clinical biochemistry and laboratory medicine, she has made significant contributions to the fields of endocrinology, diabetes, oxidative stress, and metabolic disorders.Dr. Klisic’s academic journey began at the University of Belgrade, where she earned her Doctor’s degree, Master’s degree, and Board Certification in Clinical Biochemistry. Her post-graduate specialization in Laboratory Endocrinology further strengthened her expertise in diagnostic and biochemical sciences. She has undergone advanced international training in biosafety, biosecurity, and laboratory leadership under global health programs organized in collaboration with the World Health Organization.Her research focuses on understanding the molecular and biochemical mechanisms underlying metabolic and cardiovascular diseases, emphasizing oxidative stress, inflammation, and hormonal regulation. Through her multidisciplinary studies, she explores the complex interactions between biochemical pathways and disease development, contributing to evidence-based laboratory and clinical practices.Dr. Klisic’s publications are widely recognized in high-impact scientific journals, reflecting her dedication to advancing clinical and translational research. Her work includes groundbreaking studies such as Association of Low Free T3 with Disease Presence and Activity in Ankylosing Spondylitis, Relationship Between Oxidative Stress and Cardiovascular Risk in Adolescents in Montenegro, SGLT2 Inhibitors and Cardiac Fibrosis: A Comprehensive Review, Role of Interleukins in Type 1 and Type 2 Diabetes, Oxidative Stress in Adolescents with Overweight/Obesity, and Association of Serum Selenium with Pro-atherogenic Adhesion Molecules, Inflammatory Cytokines and Carotid Intima-Media Thickness in Patients with Metabolic Syndrome. Her book chapter Antioxidant Supplementation and Cardiometabolic Syndrome (Elsevier) demonstrates her scholarly contribution to understanding reactive oxygen species and their role in chronic diseases.

Profile: Orcid

Featured Publications

Ciftel, E., Klisic, A., Kizilkaya, B., Cure, O., Mercantepe, F., Mataraci Karakas, S., & Ninić, A. (n.d.). Association of low free T3 with disease presence and activity in ankylosing spondylitis. International Journal of Molecular Sciences.

Klisic, A., Bozovic, M., Ostanek, B., Marc, J., Karakasis, P., Mercantepe, F., & Kotur-Stevuljevic, J. (n.d.). Relationship between oxidative stress and cardiovascular risk in adolescents in Montenegro. International Journal of Molecular Sciences.

Veljkovic, A., Stanojevic, G., Brankovic, B., Roumeliotis, S., Leivaditis, K., Djordjevic, B., Li, X., Klisic, A., Hadzi-Djokic, J., & Kocic, G. (n.d.). MMP-9 activation via ROS/NF-κB signaling in colorectal cancer progression: Molecular insights and prognostic–therapeutic perspectives. Current Issues in Molecular Biology.

Asif, R., Khalid, A., Mercantepe, T., Klisic, A., Rafaqat, S., Rafaqat, S., & Mercantepe, F. (n.d.). Role of interleukins in type 1 and type 2 diabetes. Diagnostics.

Pishdadian, A., Sharifi, R., Shafaghi, A., Hamedi-Shahraki, S., Amirkhizi, F., & Klisic, A. (n.d.). Association of serum selenium with clinical features and inflammatory and oxidative stress markers in Iranian patients with metabolic dysfunction-associated steatotic liver disease—A cross-sectional study. Diagnostics.

Erceg, S., Munjas, J., Sopić, M., Tomašević, R., Mitrović, M., Kotur-Stevuljević, J., Mamić, M., Vujčić, S., Klisic, A., & Ninić, A. (n.d.). Expression analysis of circulating miR-21, miR-34a and miR-122 and redox status markers in metabolic dysfunction-associated steatotic liver disease patients with and without type 2 diabetes. International Journal of Molecular Sciences.

Samavarchitehrani, A., Mercantepe, F., Behnoush, A. H., & Klisic, A. (n.d.). Exploring the TyG index and the homeostasis model assessment of insulin resistance as insulin resistance markers: Implications for fibromyalgia management and understanding—A narrative review. Diagnostics.

Ćeriman Krstić, V., Jovanović, D., Samardžić, N., Gajić, M., Kotur Stevuljević, J., Klisic, A., Soldatović, I., Radončić, D., Roksandić Milenković, M., & Šeha, B. (n.d.). The potential role of sPD-L1 as a predictive biomarker in EGFR-positive non-small-cell lung cancer. Current Issues in Molecular Biology.

Giorgio Gargari | Personalized Medicine | Best Paper Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Giorgio Gargari | Personalized Medicine | Best Paper Award

University of Milan | Italy

Assist. Prof. Dr. Giorgio Gargari is an accomplished researcher and academic in the Department of Food, Environmental and Nutritional Sciences at the University of Milan. His academic and research journey reflects a deep commitment to advancing the understanding of the intricate relationships between diet, the gut microbiome, and host physiology. With a strong foundation in biological sciences and food sciences, Dr. Gargari has developed expertise that bridges molecular biology, bioinformatics, and nutritional science, focusing on how dietary interventions influence microbiome composition and functionality. He is a highly skilled bioinformatician and biostatistician, proficient in computational biology, data analysis, and multi-omics integration. His work explores the triangular interaction between diet, microbiome, and host systems, aiming to elucidate how microbial ecosystems mediate the effects of food on health. His scientific approach integrates both experimental and computational methods to identify microbial pathways that contribute to human health and disease prevention. Dr. Gargari’s research has provided valuable insights into gut microbiome modulation through probiotics, polyphenol-rich diets, and microbial metabolites such as short-chain fatty acids. His publications demonstrate his capacity to translate complex biological data into clinically meaningful applications, particularly in the context of inflammatory regulation, gastrointestinal health, and precision nutrition.Dr. Gargari has published extensively in high-impact, peer-reviewed journals, contributing to a body of literature that continues to shape modern nutritional and microbiome research. His work has gained recognition in international conferences and scientific meetings, where he has been an invited speaker on topics such as microbial ecology in winemaking, gut microbiota modulation, and the metabolic effects of dietary components. He has also contributed to projects funded by major research institutions, coordinating studies on the transformation of agro-food waste into valuable biostimulants and microbial ecosystems for sustainable production.As an educator and academic leader, Dr. Gargari plays an active role in multiple degree programs, including Human Nutrition and Dietetics, Food Technology, and Bioinformatics for Comparative Genomics. He has supervised and mentored numerous students and has served on several thesis committees. His contributions to the scientific community have been recognized through various awards and international honors, reflecting his excellence in research, teaching, and innovation.

Profile: Orcid

Featured Publications

Gargari, G., Meroño, T., Peron, G., Del Bo’, C., Marino, M., Cherubini, A., Andres-Lacueva, C., Kroon, P. A., Riso, P., & Guglielmetti, S. (n.d.). Effect of a polyphenol-rich dietary pattern on subjects aged ≥ 60 years with higher levels of inflammatory markers: Insights into microbiome and metabolome. Microbiome Research Reports.

Marzano, M., Thakur, R. S., Bicciato, S., Raneri, M., Guglielmetti, S., Grassi, F., Mangani, D., De Ponte Conti, B., Pesole, G., Gargari, G., et al. (n.d.). Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells. Science Advances.

Laterza, L., Cremon, C., Coppola, G., Settanni, C. R., Maresca, R., Strazzeri, M., Durini, E., Petito, V., Scaldaferri, F., Gargari, G., et al. (n.d.). Multistrain probiotics plus vitamin D improve gut barrier function and gut microbiota composition in irritable bowel syndrome without constipation: Results from a double-blind, randomized, placebo-controlled trial. Nutrients.

Duncan, R., Mantegazza, G., Gargari, G., Pierallini, E., Russo, R., & Guglielmetti, S. (n.d.). Heyndrickxia coagulans LMG S-24828 is a safe probiotic strain capable of germinating in the human gut. Probiotics and Antimicrobial Proteins.

Gargari, G., Mantegazza, G., Taverniti, V., Gardana, C., Valenza, A., Rossignoli, F., Barbaro, M. R., Marasco, G., Cremon, C., Barbara, G., et al. (n.d.). Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: A potential clinically relevant stratification factor based on catabotyping analysis. Gut Microbes.

Speciani, M. C., Gargari, G., Penagini, R., Mutignani, M., Ferraroni, M., Natale, A., Katsoulis, M., Cintolo, M., Leone, P., Airoldi, A., et al. (n.d.). Garlic consumption in relation to colorectal cancer risk and to alterations of blood bacterial DNA. European Journal of Nutrition.

Mutignani, M., Penagini, R., Gargari, G., Guglielmetti, S., Cintolo, M., Airoldi, A., Leone, P., Carnevali, P., Ciafardini, C., Petrocelli, G., et al. (n.d.). Blood bacterial DNA load and profiling differ in colorectal cancer patients compared to tumor-free controls. Cancers.

Amanda Gollo Bertollo | Neuropharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Mrs. Amanda Gollo Bertollo | Neuropharmacology | Best Researcher Award

Federal University of Santa Catarina | Brazil

Mrs. Amanda Gollo Bertollo is an accomplished biomedical and neuroscience researcher with extensive experience across molecular biology, genetics, and biomedicine. Currently, she serves as a Biology Expert at Turing, providing expert review and guidance on molecular biology and genetics tasks to ensure scientific accuracy in AI-driven projects. She is pursuing her Ph.D. in Neurosciences at the Federal University of Santa Catarina, focusing on the hypothalamus-pituitary-adrenal and gut-brain axes in the biological interaction pathways of depression. Her research portfolio spans neuroscience, psychiatric disorders, and molecular mechanisms underlying mental health conditions.Previously, Mrs. Bertollo completed her Master’s in Biomedical Sciences at the Federal University of Fronteira Sul, where she conducted advanced research, authored, and critically reviewed scientific publications. She has also gained hands-on clinical and teaching experience as a Portuguese Writing Specialist at Outlier, a Personal English Teacher, and an English Instructor at Wizard Idiomas, developing personalized curricula and evaluating the accuracy of academic and creative content. Her practical biomedical training includes supervised internships in neurology at Western Regional Hospital and at the Family Health Center, where she contributed to patient care and clinical research activities. She earned her Bachelor of Science in Nursing from the Federal University of Fronteira Sul, providing a strong foundation in patient care, biomedical research, and clinical practice. Additionally, she is pursuing undergraduate studies in Computer Science, reflecting her interdisciplinary approach bridging computational methods with biological and clinical research.Mrs. Bertollo has authored and contributed to numerous influential publications, including “Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression,” “Neurobiological Relationships Between Neurodevelopmental Disorders and Mood Disorders,” and “Biological rhythms and psychiatric symptoms in COVID-19 individuals: a cross-sectional multicentric study.” Her work further explores topics such as the impact of melatonin on cytokine storms and purinergic receptor modulation for COVID-19 prognosis, dementia and depression connections with amyloid β protein, early life stress and major depressive disorder, depressive-like behaviors influenced by Centella asiatica extracts, neurobiological mechanisms in the kynurenine pathway, peripheral biomarkers predicting COVID-19 prognosis, and the role of ABO blood type and metabolic markers in COVID-19 susceptibility and severity. Through her multidisciplinary research, Mrs. Bertollo has made substantial contributions to the understanding of neurobiological pathways, psychiatric disorders, and the clinical implications of metabolic and immunological biomarkers, establishing herself as a rising expert in neurosciences and biomedical sciences.

Profile: Orcid

Featured Publications

Bertollo, A. G., Santos, C. F., Bagatini, M. D., & Ignácio, Z. M. Hypothalamus-pituitary-adrenal and gut-brain axes in biological interaction pathway of the depression. Frontiers in Neuroscience.

Bertollo, A. G., Mocelin, R., & Ignácio, Z. M. Pharmacogenetics and the response to antidepressants in major depressive disorder. Pharmaceuticals.

Mattia-Maximiano, B. C., Mioranza-Koppe, M., Silva, R. H., Arent, C. O., Amboni, G., Pedro, L. C., Bertollo, A. G., Dellazeri Cortez, A., de Medeiros, J., Pedrotti Moreira, F., et al. Biological rhythms and psychiatric symptoms in COVID-19 individuals: a cross-sectional multicentric study. Biological Rhythm Research.

Bertollo, A. G., Puntel, C. F., da Silva, B. V., Martins, M., Bagatini, M. D., & Ignácio, Z. M. Neurobiological relationships between neurodevelopmental disorders and mood disorders. Brain Sciences.

Bertollo, A. G., Mingoti, M. E. D., & Ignácio, Z. M. Neurobiological mechanisms in the kynurenine pathway and major depressive disorder. Reviews in the Neurosciences.

Bertollo, A. G., da Silva, B. V., Martins, M., Bagatini, M. D., & Ignácio, Z. M. Neurobiological relationships between neurodevelopmental disorders and mood disorders.

Liangxing Tu | Drug Delivery Systems | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Liangxing Tu | Drug Delivery Systems | Best Researcher Award

Jiangxi University of Chinese Medicine | China

Prof. Dr. Liangxing Tu is a distinguished pharmaceutical scientist recognized for his extensive contributions to drug delivery systems and biopharmaceutics. He earned his Ph.D. in Pharmaceutics from the Shanghai University of Traditional Chinese Medicine, where he developed a strong foundation in advanced pharmaceutical formulations and nanotechnology-based therapeutics. After completing his doctoral studies, he began his professional journey at FosunPharma in Shanghai, where he contributed to pharmaceutical innovation and product development. He later joined the Jiangxi University of Traditional Chinese Medicine, where he currently serves as the Director of the Division of Innovative Pharmaceutical Sciences, leading cutting-edge research in formulation science and nanomedicine.Dr. Tu’s research focuses on developing advanced drug delivery systems, including nanocrystals, polymeric micelles, and vesicular systems, to enhance the oral bioavailability and therapeutic efficacy of poorly soluble drugs. His work also extends to exploring biopharmaceutics mechanisms to improve the in vivo performance of active pharmaceutical ingredients. His innovative approaches have positioned him at the forefront of translational pharmaceutics, bridging the gap between laboratory research and clinical applications.He is an active member of the Chinese Pharmaceutical Association and contributes his expertise as a member of the Elsevier Advisory Panel. Additionally, he serves on the Editorial Board of Chinese Chemical Letters (ISSN: 1001-8417), reflecting his strong academic presence and influence in the pharmaceutical sciences community. Dr. Tu has been awarded multiple research grants, including projects funded by the National Natural Science Foundation of China and other governmental bodies, underscoring the national and international recognition of his research excellence.Dr. Tu has published around 30 peer-reviewed papers in top-tier journals such as Chinese Chemical Letters, Drug Delivery, and the International Journal of Pharmaceutics. His representative publications include “Vesicular Drug Delivery Systems for Oral Absorption Enhancement,” “Multi-functional Chitosan Copolymer Modified Nanocrystals as Oral Andrographolide Delivery Systems for Enhanced Bioavailability and Anti-inflammatory Efficacy,” “Fabrication of Ultra-Small Nanocrystals by Formation of Hydrogen Bonds: In Vitro and In Vivo Evaluation,” “Multi-functional Chitosan Polymeric Micelles as Oral Paclitaxel Delivery Systems for Enhanced Bioavailability and Anti-Tumor Efficacy,” and “Study on the Preparation of Stabilizer-Free Silymarin Nanocrystals and Its Oral Absorption Mechanisms.”

Profile: Orcid

Featured Publications

Wang, J., Sun, Y., Meng, L., Feng, J., Cheng, M., & Tu, L. Intestinal transporters and oral absorption enhancing strategies based on these transporters. Chinese Chemical Letters.

Li, Z., Yao, L., Liu, Z., Wang, L., Ruan, H., Shen, Y., Zhang, P., Li, K., Wang, H., Fan, L., et al. Andrographolide Sulfonates and Xiyanping: A Review of Chemical Composition, Pharmacological Activities, Clinical Applications, and Adverse Reactions. Pharmaceuticals.

Tu, L., Wang, J., Sun, Y., & Wan, Y. Fabrication of Luteolin Nanoemulsion by Box-Behnken Design to Enhance its Oral Absorption Via Lymphatic Transport. AAPS PharmSciTech.

Zou, L., Cheng, M., Hu, K., Feng, J., & Tu, L. Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters.

He, Y., Cheng, M., Yang, R., Li, H., Lu, Z., Jin, Y., Feng, J., & Tu, L. Research Progress on the Mechanism of Nanoparticles Crossing the Intestinal Epithelial Cell Membrane. Pharmaceutics.

Liu, W., Cheng, M., Yuan, F., He, J., Feng, Y., Jin, Y., Yang, S., Feng, J., & Tu, L. Enhancing oral bioavailability of andrographolide via sodium dodecyl sulfate and D-α-Tocopherol polyethylene glycol 1000 succinate copolymer modified nanocrystals. Journal of Drug Delivery Science and Technology.

Liu, W., Cheng, M., Lu, Z., Li, H., Feng, Y., Jin, Y., Yang, S., Feng, J., & Tu, L. Multi-functional chitosan copolymer modified nanocrystals as oral andrographolide delivery systems for enhanced bioavailability and anti-inflammatory efficacy. Drug Delivery.

Zefeng Lai | Drug Delivery Systems | Excellence in Pharmaceutical Innovation Award

Published on by Top Pharmaceutical

Prof. Dr. Zefeng Lai | Drug Delivery Systems | Excellence in Pharmaceutical Innovation Award

Guangxi Medical University | China

Prof. Dr. Zefeng Lai is a leading figure in the field of pharmaceutical science, recognized for his pioneering work in nanomedicine, drug delivery, and nanotoxicology. He serves as a Professor of Pharmaceutical Science at the School of Pharmacy, Guangxi Medical University, Nanning, China, where he has made outstanding contributions to biomedical research and academic development. Having earned his BSc and PhD from the State Key Laboratory of Crystal Materials, Shandong University, and completed postdoctoral research in Drug Delivery and Biomedical Effects of Nanomaterials, Dr. Lai’s expertise integrates material chemistry with pharmacological innovation to enhance therapeutic outcomes.His research explores the mechanisms and biomedical applications of carbon-based nanodrug carriers, focusing on their transcytosis, biodistribution, and immunological effects. He has led multiple high-impact national and provincial projects, including investigations into mesona chinensis polysaccharides, fibrinolytic enzymes from marine sources, and liver-targeted nanocarriers. His work on the biotoxicity of carboxylated single-walled carbon nanotubes using zebrafish and mammalian models has been particularly influential, advancing the global understanding of nanomaterial safety in pharmaceutical formulations.Prof. Lai’s scholarly influence is reflected in his strong research metrics, with 293 citations across 279 documents, based on 19 published papers, and an impressive h-index of 10, demonstrating his consistent impact and the recognition of his contributions by the global scientific community.His groundbreaking publications demonstrate his multidisciplinary research vision. His paper Photothermal Therapeutic Gold Nanoparticles Loaded with PD-L1 siRNA Enhanced Killing of NSCLC Cells by Immune Cells presents a novel nanoplatform integrating photothermal therapy and immunomodulation for non-small cell lung cancer treatment. His work Immunogenic Nano-Phthalocyanine Enables Oxygen-Economic Photodynamic Therapy for Hepatocellular Carcinoma introduces a new generation of oxygen-efficient nanotherapeutics for liver cancer. Other notable studies include Effect of Carboxylated Single-Walled Carbon Nanotubes on the Development and Morphology of Zebrafish Embryos, High Throughput CircRNA Sequencing Analysis Reveals Novel Insights into the Mechanism of Nitidine Chloride against Hepatocellular Carcinoma, and Toxic Effect of Long-Term Intravenous Injection of Carboxylated Single-Walled Carbon Nanotubes on Kidney in Rats. His research on Nitidine Chloride Induced Colorectal Cancer HT29 Cells Apoptosis Through the Cytochrome c-Mediated Mitochondrial Pathways and Long-Term Intravenous Administration of Carboxylated Single-Walled Carbon Nanotubes Induces Persistent Accumulation in the Lungs and Pulmonary Fibrosis via the NF-κB Pathway underscores his deep engagement with molecular pharmacology and nanotoxicology.

Profile: Scopus

Featured Publications

Lai, Z., Liu, Y., He, L., Wang, X., Zhang, H., & Zhao, J. (2023). Immunogenic nano-phthalocyanine enables oxygen-economic photodynamic therapy for hepatocellular carcinoma. Biomaterials, 295, 121992.

Narendra Bagri | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Narendra Bagri | Clinical Trials | Best Researcher Award

All India Institute of Medical Sciences | India

Assoc. Prof. Dr. Narendra Bagri is a distinguished clinician and academician in the field of pediatric rheumatology, presently serving as Additional Professor in the Department of Pediatrics, Division of Pediatric Rheumatology at the All India Institute of Medical Sciences (AIIMS), New Delhi, India. A graduate and postgraduate of the Institute of Medical Sciences, Banaras Hindu University, he has built a remarkable career through a blend of clinical excellence, teaching, and groundbreaking research in pediatric autoimmune and inflammatory disorders. He completed the prestigious PRES EMERGE Fellowship in Pediatric Rheumatology at the Bristol Royal Hospital for Children, UK, under the mentorship of Prof. A.V. Ramanan, enhancing his expertise in advanced pediatric rheumatologic care and translational research.Dr. Bagri’s scientific contributions encompass numerous impactful publications addressing critical aspects of pediatric inflammatory diseases, musculoskeletal imaging, and immunological mechanisms underlying juvenile idiopathic arthritis. His research includes the longitudinal analysis of multisystem inflammatory syndrome in children temporally related to COVID-19, the evaluation of pulse dexamethasone therapy in non-systemic juvenile idiopathic arthritis, and the technical and interpretive insights into pediatric musculoskeletal ultrasound. He has also authored work on the utility of musculoskeletal ultrasound in juvenile idiopathic arthritis, the forgotten figure in the history of methotrexate, sympathetic blocks for Raynaud’s phenomena in pediatric rheumatological disorders, and the conception of a national biologics registry for pediatric rheumatology.As a principal investigator and collaborator in multiple funded research projects by the Indian Council of Medical Research (ICMR) and the Science and Engineering Research Board (SERB), Dr. Bagri has contributed extensively to the understanding of synovial fluid proteomics, biomarker discovery, and immune-pathogenic mechanisms in childhood arthritis. His pioneering efforts include the development of transitional care services, collaborative rheumatology clinics, and the initiation of diagnostic and therapeutic procedures such as ultrasound-guided intra-articular injections and synovial biopsies.Dr. Bagri is a life member of several professional bodies, including the Indian Rheumatology Association, the Pediatric Rheumatology European Society, and the Indian Academy of Pediatrics. Recognized for his outstanding contributions, he has received multiple academic honors, travel grants, and leadership roles in national guideline formulation, including contributions to WHO and IAP documents on pediatric inflammatory syndromes. His dedication to research, patient care, and education continues to shape the evolution of pediatric rheumatology in India and beyond.

Profile: Google Scholar

Featured Publications

Bagri, N. K., Jose, B., Shah, S. K., Bhutia, T. D., Kabra, S. K., & Lodha, R. (n.d.). Impact of malnutrition on the outcome of critically ill children. The Indian Journal of Pediatrics, 82(7), 601–605.

Sivasubbu, S., & Scaria, V. (n.d.). Genomics of rare genetic diseases—experiences from India. Human Genomics.

Basu, S., Kumar, A., Kapoor, K., Bagri, N. K., & Chandra, A. (n.d.). Neonatal endogenous endophthalmitis: A report of six cases. Pediatrics.

Bagri, N., Saha, A., Chandelia, S., Dubey, N. K., Bhatt, A., Rai, A., & Bhattacharya, S. (n.d.). Fireworks injuries in children: A prospective study during the festival of lights. Emergency Medicine Australasia.

Bagri, N. K., Yadav, D. K., Agarwal, S., Aier, T., & Gupta, V. (n.d.). Pericardial effusion in children: Experience from tertiary care center in northern India. Indian Pediatrics.

Kumar, A., Bagri, N. K., Basu, S., & Asthana, R. K. (n.d.). Zinc supplementation for neonatal hyperbilirubinemia: A randomized controlled trial. Indian Pediatrics.

Bagri, N. K., Deepak, R. K., Meena, S., Gupta, S. K., Prakash, S., Setlur, K., Satapathy, J., Chopra, K., Upadhyay, A. D., Ramakrishnan, S., Lodha, R., Dar, L., Trikha, A., & Kabra, S. K. (n.d.). Outcomes of multisystem inflammatory syndrome in children temporally related to COVID-19: A longitudinal study. Rheumatology International.

Gupta, D., Thakral, D., Kumar, P., Kabra, S. K., Lodha, R., Kumari, R., Mohanty, S. K., … & Bagri, N. K. (n.d.). Primary immunodeficiency disorders among north Indian children. The Indian Journal of Pediatrics.

Radhakrishnanand Pullapanthula | Pharmaceutical Analysis |

Published on by Top Pharmaceutical

Prof. Dr. Radhakrishnanand Pullapanthula | Pharmaceutical Analysis | Best Researcher Award

National Institute of Pharmaceutical Education and Research | India

Prof. Dr. Radhakrishnanand Pullapanthula is a highly accomplished pharmaceutical scientist and analytical research leader with over two decades of distinguished experience in both industry and academia. A quality-minded professional, he has built a reputation for excellence in analytical compliance, regulatory affairs, and strategic development in the pharmaceutical sector. With a career spanning more than 24 years, including over 12 years in senior management positions, Dr. Pullapanthula has contributed significantly to analytical research and development, project leadership, and regulatory compliance within the framework of international standards such as cGMP, FDA, and ICH. His expertise lies in analytical method development, impurity profiling, physico-chemical characterization, and life cycle management of complex pharmaceutical products, including ANDA and NDA applications.Dr. Radhakrishnanand has been a driving force in setting up GMP-compliant analytical laboratories and implementing best practices for quality and regulatory adherence. His technical mastery covers LC-MS/MS, GC-MS/MS, ICP-MS, LC-Q-TOF-MS/MS, HPLC, GC, and IC techniques, enabling him to develop and validate advanced analytical methods for drug substances, formulations, excipients, food, and herbal products. His pioneering work in impurity profiling, degradation chemistry, and reference standard qualification has had a lasting impact on analytical R&D and pharmaceutical quality systems. As a leader, he has successfully coordinated the establishment of ISO 17025:2005 and ISO 17025:2017 certified laboratories, and played a key role in achieving NABL accreditation and ISO certification for analytical facilities at Daicel Chiral Technologies–India and United States Pharmacopeia.In addition to his industrial achievements, Dr. Radhakrishnanand has held prominent academic and administrative roles, serving as Registrar (In-Charge) and a board-level member in key scientific and innovation committees. His contributions extend to serving as an Expert Member on several national panels including the DST-Technology Development Board, ANRF-Life Sciences, NGCMA, and the Pharmaceutical Policy Committee of Tripura. As a Board of Director at the Atal Innovation Mission, NIPER-Guwahati, he has actively promoted innovation and research excellence in the pharmaceutical sciences. He currently manages and coordinates major projects such as the “Quality Assessment and Value Addition Centre for Herbal Industry in the North-Eastern States of India,” funded by the Ministry of Commerce under the TIES scheme, with a project worth exceeding twenty crores.

Profile: Google Scholar

Featured Publications

Rao, D. V. S., Radhakrishnanand, P., Suryanarayana, M. V., & Himabindu, V. (n.d.). A stability-indicating LC method for candesartan cilexetil. Chromatographia.

Kumari Rayala, V. V. S. P., Kandula, J. S., & Radhakrishnanand, P. (n.d.). Advances and challenges in the pharmacokinetics and bioanalysis of chiral drugs. Chirality.

Rao, D. V. S., & Radhakrishnanand, P. (n.d.). Stress degradation studies on dutasteride and development of a stability-indicating HPLC assay method for bulk drug and pharmaceutical dosage form. Chromatographia.

Kaja, R. K., Surendranath, K. V., Radhakrishnanand, P., Satish, J., & others. (n.d.). A stability-indicating LC method for deferasirox in bulk drugs and pharmaceutical dosage forms. Chromatographia.

Vishnuvardhan, C., Radhakrishnanand, P., Navalgund, S. G., Atcha, K. R., & others. (n.d.). RP-HPLC method for the simultaneous estimation of eight cardiovascular drugs. Chromatographia.

Rao, D. V. S., Radhakrishnanand, P., & Himabindu, V. (n.d.). Stress degradation studies on tadalafil and development of a validated stability-indicating LC assay for bulk drug and pharmaceutical dosage form. Chromatographia.

Subba Rao, D. V., Surendranath, K. V., Radhakrishnanand, P., & others. (n.d.). A stability-indicating LC method for vardenafil HCl. Chromatographia.